Back to Results
First PageMeta Content
Biology / Growth hormones / Growth factors / Endocrinology / Recombinant proteins / Insulin-like growth factor 1 / Mecasermin / Insulin-like growth factor / Laron syndrome / Endocrine system / Peptide hormones / Medicine


Microsoft Word - E03-P-a Policy Mecasermin
Add to Reading List

Document Date: 2013-08-13 12:09:53

Open Document

File Size: 318,79 KB

Share Result on Facebook

Company

All Wales Medicines Strategy Group / /

Country

United States / United Kingdom / Wales / /

Currency

GBP / /

Event

FDA Phase / /

Facility

National Institute of Health / /

IndustryTerm

orphan medicinal product / Treatment of Growth Failure / /

MedicalCondition

malnutrition / insulin resistance / This disorder / disease / hypothyroidism / learning disability / chronic treatment / genetic disorder / Introduction Growth hormone insensitivity syndrome / muscle weakness / bone disease / severe primary insulin-like growth factor1 deficiency / Laron syndrome / obesity / disorder / osteoporosis / growth disorders / autosomal recessive disorder / deficiency / GH deficiency / syndrome / disorders / /

MedicalTreatment

hormone treatment / /

Organization

NHS Commissioning Board / National Institute of Health / European Union / NHS / The Bedfordshire and Luton Joint Prescribing Committee / /

Product

Mecasermin / Lupron / Increlex / Increlex® / /

Technology

one protocol / antibodies / GPS / recombinant DNA / /

SocialTag